SCHEMBL12634843

SCHEMBL12634843

O=S1(=O)Cc2nc(-c3ccnc(Cl)c3)nc(Cl)c2C1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IDO1 P14902 2/20 0.35
▸ PDE4B Q07343 6/20 0.34
▸ PARP10 Q53GL7 1/20 0.34
▸ PARP11 Q9NR21 1/20 0.34
▸ CYP19A1 P11511 1/20 0.33
▸ S1PR1 P21453 3/20 0.32
▸ S1PR3 Q99500 2/20 0.32
▸ CDC7 O00311 1/20 0.32
▸ ROCK2 O75116 1/20 0.32
▸ MAP4K4 O95819 1/20 0.32
▸ CDK2 P24941 1/20 0.32
▸ MAPKAPK2 P49137 1/20 0.32
▸ GSK3B P49841 1/20 0.32
▸ HIPK2 Q9H2X6 1/20 0.32
▸ CLK4 Q9HAZ1 1/20 0.32
▸ IRAK4 Q9NWZ3 1/20 0.32
▸ CCNC P24863 1/20 0.32
▸ CDK8 P49336 1/20 0.32
▸ ADORA2A P29274 1/20 0.32
▸ ADORA1 P30542 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16180207 0.78 PDE4B (0.34) PDE4B
SCHEMBL12634821 0.75 PDE4B (0.33) PDE4B
SCHEMBL12634826 0.75 HRH4 (0.34) PDE4B
SCHEMBL12634764 0.75 IDO1 (0.37) IDO1PDE4BPARP10PARP11CYP19A1
SCHEMBL12634839 0.73 PDE4B (0.32) PDE4B
SCHEMBL23348686 0.72 IDO1 (0.53) IDO1PARP10PARP11CYP19A1S1PR1
SCHEMBL12634812 0.69 TP53 (0.30) —
SCHEMBL12634837 0.69 ALDH1A1 (0.31) —
SCHEMBL14095199 0.66 AXL (0.44) IDO1PDE4BCYP19A1ADORA2AADORA1
SCHEMBL18253554 0.65 ADORA2A (0.54) IDO1CYP19A1S1PR1S1PR3ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7947690-B2 Insulin secretagogue and hypoglycemic agent; pyrimidine derivatives condensed with a non-aromatic ring selected from dihydrothiophene, dihydrofuran, cycloalkane moiety; 1-[2-(4-chloro-2,5-difluorophenyl)-6,6-dioxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl]-4-(3-hydroxypropyl)piperidin-4-ol for example ASTELLAS PHARMA INC. (JP) 2011-05-24 — — US disclosed
US-7947690-B2 Insulin secretagogue and hypoglycemic agent; pyrimidine derivatives condensed with a non-aromatic ring selected from dihydrothiophene, dihydrofuran, cycloalkane moiety; 1-[2-(4-chloro-2,5-difluorophenyl)-6,6-dioxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl]-4-(3-hydroxypropyl)piperidin-4-ol for example ASTELLAS PHARMA INC. (JP) 2011-05-24 — — US disclosed
US-20080070896-A1 Pyrimidine Derivative Condensed with a Non-Aromatic Ring ASTELLAS PHARMA INC. (JP) 2008-03-20 — — US disclosed
US-20080070896-A1 Pyrimidine Derivative Condensed with a Non-Aromatic Ring ASTELLAS PHARMA INC. (JP) 2008-03-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080070896-A1 Pyrimidine Derivative Condensed with a Non-Aromatic Ring GPR119, IRS1, NONO IDO1 617/4885PDE4B 3723/4885PARP10 3880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback